Physician profile
Michael Lyons
NPI 1215970595
$1,518.54
in general payments reported to CMS, 2019-2025
21 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $173 · 2021: $199 · 2022: $311 · 2023: $244 · 2024: $255 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $280.64 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $205.22 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $186.42 | 2019-2021 | |
| Novo Nordisk INC | $164.77 | 2022-2025 | Ozempic |
| Glaxosmithkline, LLC. | $124.76 | 2020 | |
| Gilead Sciences, INC. | $95.11 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $63.34 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Intra-Sana Laboratories | $50.00 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Exact Sciences Corporation | $48.45 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $43.20 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $35.47 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.52 | 2020 | |
| Phathom Pharmaceuticals, INC. | $29.88 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $27.69 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $26.61 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $21.57 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.67 | 2022 | |
| Amgen INC. | $17.31 | 2023 | Otezla, Repatha |
| Medtronic Vascular, INC. | $15.53 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.45 | 2022 | |
| Esperion Therapeutics, INC. | $14.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.